Case Report
Published on 16 Jan 2025
Case report: VEXAS syndrome: first documented cases in Latin America
Frontiers in Hematology
doi 10.3389/frhem.2024.1501337
- 131 views
Volumes
112 Publications
Volume 3 - 2024
Case Report
Published on 10 Jan 2025
Case report: A decade-long journey with cyclic thrombocytopenia
Frontiers in Hematology
doi 10.3389/frhem.2024.1482891
Original Research
Accepted on 30 Dec 2024
Impact of leukaemia subtype and demographics on patient quality of life in 76 countries: a cross-sectional study
Frontiers in Hematology
doi 10.3389/frhem.2024.1502166
Original Research
Published on 26 Dec 2024
Unique target binding by the C-terminal region of FHR1 provides a new perception of aHUS pathology
Frontiers in Hematology
doi 10.3389/frhem.2024.1469176
- 411 views
Mini Review
Published on 24 Dec 2024
Leveraging big data and artificial intelligence for smarter trials in myeloproliferative neoplasms
Frontiers in Hematology
doi 10.3389/frhem.2024.1504327
- 335 views
Case Report
Published on 17 Dec 2024
A patient with concurrent EBV-negative diffuse large B-cell lymphoma and angioimmunoblastic T-cell lymphoma: a case report
Frontiers in Hematology
doi 10.3389/frhem.2024.1463487
- 282 views
Case Report
Published on 12 Dec 2024
Ruxolitinib and pegylated interferon in Chronic Neutrophilic Leukemia due to a pathogenic CSF3R germline variant: a case report
Frontiers in Hematology
doi 10.3389/frhem.2024.1508463
- 179 views
Case Report
Published on 09 Dec 2024
Case report: Vitamin B12 deficiency-associated hemolytic anemia
Frontiers in Hematology
doi 10.3389/frhem.2024.1446241
- 602 views
Study Protocol
Published on 06 Dec 2024
Comparison of 6 cycles of isatuximab with lenalidomide, bortezomib and dexamethasone (I-VRd) versus 3 cycles of I-VRd followed by one cycle of high-dose melphalan in newly diagnosed low-risk multiple myeloma. Protocol for a multicenter, prospective, randomized, phase II clinical trial (ELIAS-Trial)
Frontiers in Hematology
doi 10.3389/frhem.2024.1436845
- 614 views
Original Research
Published on 05 Dec 2024
Prevalence of measurable residual disease in patients with refractory/relapsed multiple myeloma who reached complete response: a cross-sectional multicentric study
Frontiers in Hematology
doi 10.3389/frhem.2024.1480120
- 346 views
Review
Published on 03 Dec 2024
Delineation of erythropoietic intermediates by flow cytometry
Frontiers in Hematology
doi 10.3389/frhem.2024.1496916
- 275 views
Original Research
Published on 02 Dec 2024
Rare cell-based liquid biopsy for improved measurement of low-grade chronic inflammation
Frontiers in Hematology
doi 10.3389/frhem.2024.1472609
- 198 views
Original Research
Published on 26 Nov 2024
Exploring the regenerative capacity of the spleen following irradiation
Frontiers in Hematology
doi 10.3389/frhem.2024.1396672
- 229 views
Original Research
Published on 22 Nov 2024
Distinct clinico-genomic factors drive outcomes in patients with myelofibrosis and disease-related anemia
Frontiers in Hematology
doi 10.3389/frhem.2024.1492680
- 235 views
Volume 4 - 2025
Editorial
Accepted on 02 Jan 2025
Editorial: Two Decades of Targeted Therapies in Hematology -New Targets and Novel Combinations
Frontiers in Hematology
doi 10.3389/frhem.2025.1548984
Mini Review
Accepted on 02 Jan 2025
The aging hematopoietic stem cell niche: a mini review
Frontiers in Hematology
doi 10.3389/frhem.2025.1525132